财通证券股份有限公司 关于济民健康管理股份有限公司 专项现场检查报告 1、查阅公司披露的《关于公司副总裁涉嫌犯罪及公司报案并收到立案通知 书的公告》、《关于解聘公司副总裁的公告》以及《2024 年年度业绩预亏更正 的公告》等相关公告，了解该事项发生的经过。 2、查阅公司三会文件、内部控制制度以及以前年度《内部控制审计报 告》、《内部控制评价报告》，核查公司内部控制有效性。 3、对公司董事会秘书进行访谈，详细了解针对本事项公司采取的措施以及 对公司未来生产经营等的影响。 （二）公司采取的措施及保荐机构意见 1、积极配合公安机关调查，追偿公司损失； 财通证券股份有限公司（以下简称"财通证券"、"保荐机构"）作为济民健 康管理股份有限公司（以下简称"济民健康"、"上市公司"、"公司"）持续督导 工作的保荐机构，根据《证券发行上市保荐业务管理办法》《上海证券交易所 股票上市规则》《上海证券交易所上市公司自律监管指引第 11 号—持续督导》 （以下简称"《持续督导》"）等有关法律法规和规范性文件的要求，对济民 健康进行了专项现场检查，有关核查情况具体说明如下: 一、现场检查的基本情况 2025 年 3 月 26 日，济 ...

公司代码：603222 公司简称：济民健康 济民健康管理股份有限公司 2024年度内部控制评价报告 济民健康管理股份有限公司全体股东： 根据《企业内部控制基本规范》及其配套指引的规定和其他内部控制监管要求（以下简称企业内部 控制规范体系），结合本公司（以下简称公司）内部控制制度和评价办法，在内部控制日常监督和专项 监督的基础上，我们对公司2024年12月31日（内部控制评价报告基准日）的内部控制有效性进行了评价。 一. 重要声明 按照企业内部控制规范体系的规定，建立健全和有效实施内部控制，评价其有效性，并如实披露内 部控制评价报告是公司董事会的责任。监事会对董事会建立和实施内部控制进行监督。经理层负责组织 领导企业内部控制的日常运行。公司董事会、监事会及董事、监事、高级管理人员保证本报告内容不存 在任何虚假记载、误导性陈述或重大遗漏，并对报告内容的真实性、准确性和完整性承担个别及连带法 律责任。 公司内部控制的目标是合理保证经营管理合法合规、资产安全、财务报告及相关信息真实完整，提 高经营效率和效果，促进实现发展战略。由于内部控制存在的固有局限性，故仅能为实现上述目标提供 合理保证。此外，由于情况的变化可能导 ...

关于对济民健康管理股份有限公司 2024 年度财务报表发表非标准审计意见的 专项说明 天健函〔2025〕323 号 济民健康管理股份有限公司全体股东： 我们接受委托，审计了济民健康管理股份有限公司（以下简称济民健康）2024 年度的财务报表，并出具了带强调事项段的无保留意见的《审计报告》（天健审 〔2025〕8808 号）。根据《公开发行证券的公司信息披露编报规则第 14 号—— 非标准审计意见及其涉及事项的处理（2020 年修订）》和《监管规则适用指引— —审计类第 1 号》相关要求，现将济民健康有关情况说明如下： 一、审计报告中强调事项段所涉及事项 如审计报告中"强调事项"段所述，我们提醒财务报表使用者关注，如财务 报表附注十五（三）3 所述，截至财务报告批准报出日，济民健康已就"何清红 等人伪造公司印章"事项向公安机关报案。经咨询律师专业意见，并根据经销商 库存摸排情况，结合预备解决方案，济民健康基于谨慎性原则预计了相关损失 2,831.71 万元。本段内容不影响已发表的审计意见。 济民健康已就本说明一强调事项段所涉及事项在财务报表中作出了恰当列 报。我们认为，强调事项段所涉及事项不会导致发表非无保留意 ...

济民健康管理股份有限公司 关于使用部分闲置自有资金进行现金管理的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示： ●现金管理额度：公司及子公司总额不超过人民币 20,000 万元 ，在额度内 资金可以滚动使用。 证券代码：603222 证券简称：济民健康 公告编号：2025-019 ●现金管理产品类型：投资安全性高、流动性好、短期保本型或低风险型理 财产品。 ●现金管理决策有效期：自董事会审议通过之日起 12 个月内有效。 济民健康管理股份有限公司（以下简称"公司"）2025年4月27日召开第五 届董事会第十八次会议审议通过了《关于使用部分闲置自有资金进行现金管理的 议案》，同意公司使用最高额不超过20,000万元（含本数）的闲置自有资金进行 现金管理。使用期限自公司董事会审议通过之日生效，授权期限不超过12个月， 在上述额度及决议有效期内，可循环滚动使用。 现将相关事项公告如下： 一、本次使用闲置自有资金进行现金管理的基本情况 1、现金管理目的 在确保日常经营资金需求和资金安全的前提下，对闲置自有资 ...

证券代码：603222 证券简称：济民健康 公告编号：2025-021 济民健康管理股份有限公司 2024 年度募集资金存放与使用情况的专项报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 根据中国证券监督管理委员会《关于核准济民健康管理股份有限公司非公开 发行股票的批复》（证监许可〔2022〕2864 号），本公司由主承销商财通证券 股份有限公司采用非公开发行新股方式，向特定对象非公开发行人民币普通股（A 股）股票 60,196,560 股，发行价为每股人民币 8.14 元，共计募集资金 489,999,998.40 元，坐扣承销费（不含税）5,859,999.98 元后的募集资金为 484,139,998.42 元，已由主承销商财通证券股份有限公司于 2022 年 12 月 29 日 汇入公司募集资金监管账户。另减除保荐费 1,000,000.00 元和律师费、审计及 验资费、法定信息披露等其他发行费用 2,346,798.42 元后，本公司本次募集资 金净额为 480,793,200.00 元。上述募集资金到位 ...

●日常关联交易对上市公司的影响：公司与关联方发生的日常关联交易均按 照公平、公正、自愿、诚信的原则进行，不会对公司的独立性产生影响，不会对 关联方形成依赖。 一、日常关联交易基本情况 （一）日常关联交易履行的审议程序 证券代码：603222 证券简称：济民健康 公告编号：2025-017 济民健康管理股份有限公司 关于预计2025年度日常关联交易的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示： ●是否需要提交股东会审议：否 济民健康管理股份有限公司（以下简称"公司"）第五届董事会第十八次会 议于2025年4月27日召开，审议通过了《关于预计公司2025年日常关联交易的议案》， 关联董事李丽莎、田云飞回避表决。本关联交易事项在提交董事会审议前已经公 司独立董事专门会议审议通过。 （二）前次日常关联交易的预计和执行情况 | 单位：万元 | | --- | | | | 上年（前次） | 上年（前次） | 预计金额与实际 | | --- | --- | --- | --- | --- | | 关联交易类别 ...

2024 年度公司审计委员会对会计师事务所履行监督职责情况报告 济民健康管理股份有限公司 关于 2024 年度董事会审计委员对会计师事务所履职 监督职责情况的报告 济民健康管理股份有限公司（以下简称"公司"）聘请天健会计师事务所（特 殊普通合伙）（以下简称"天健"）作为公司 2024 年年度审计会计师事务所。根 据《国有企业、上市公司选聘会计师事务所管理办法》等相关规定，现将公司董 事会审计委员会对会计师事务所 2024 年度履职情况评估及履行监督职责情况报 告如下： 一、会计师事务所基本情况 | 1、基本信息 | | | | --- | --- | --- | | 事务所名称 | 天健会计师事务所（特殊普通合伙） | | | 成立日期 | 2011 年 7 月 18 日 | 组织形式 特殊普通合伙 | | 注册地址 | 浙江省杭州市西湖区灵隐街道西溪路 | 128 号 | | 首席合伙人 | 钟建国 | 上年末合伙人数量 241 人 | | 上年末执业人 | 注册会计师 | 2,356 人 | | 员数量 | 签署过证券服务业务审计报告的注册会计师 | 904 人 | | 2023 年（经审 | 业务收入总 ...

公司对会计师事务所 2024 年度履职情况的评估报告 公司对会计师事务所 2024 年度履职情况的评估报告 济民健康管理股份有限公司 对会计师事务所 2024 年度履职情况的评估报告 济民健康管理股份有限公司（以下简称"公司"）聘请天健会计师事务所（特 殊普通合伙）（以下简称"天健事务所"）为公司 2024 年度财务报告审计机构 及内部控制审计机构。根据财政部、国务院国有资产监督管理委员会及中国证券 监督管理委员会颁布的《国有企业、上市公司选聘会计师事务所管理办法》，公 司对天健事务所 2024 年度审计过程中的履职情况进行了综合评估。经评估，公 司认为天健事务所资质等方面合规有效，履职保持独立性，勤勉尽责，公允表达 意见。具体情况如下： 一、会计师事务所情况 | 事务所名称 | 天健会计师事务所（特殊普通合伙） | | | | | | | --- | --- | --- | --- | --- | --- | --- | | 成立日期 | 2011 年 7 月 日 组织形式 | 18 | | | 特殊普通合伙 | | | 注册地址 | 浙江省杭州市西湖区灵隐街道西溪路 | | 128 号 | | | | | ...

Financial Performance - The company's operating revenue for Q1 2025 was ¥181,021,832.06, a decrease of 22.49% compared to ¥233,537,436.40 in the same period last year[4] - The net profit attributable to shareholders was -¥13,636,453.43, representing a decline of 191.72% from ¥14,866,868.40 in the previous year[4] - Basic and diluted earnings per share were both -¥0.03, a decrease of 200.00% compared to ¥0.03 in the same period last year[4] - The company reported a net loss for Q1 2025, with total operating income not covering total operating costs, leading to a negative operating margin[18] - The net profit for Q1 2025 was -11,697,676.54 RMB, compared to a net profit of 18,511,661.11 RMB in Q1 2024, indicating a significant decline[19] - The total profit for Q1 2025 was -14,839,624.24 RMB, down from 19,906,503.49 RMB in the same period last year[19] - Operating profit for Q1 2025 was -14,724,154.15 RMB, compared to 21,081,215.94 RMB in Q1 2024, reflecting a substantial decrease[19] - The company reported a comprehensive income total of -9,220,897.65 RMB for Q1 2025, compared to 16,685,700.84 RMB in Q1 2024[20] Cash Flow and Assets - The net cash flow from operating activities increased by 172.61%, reaching ¥34,515,778.21, primarily due to insurance compensation received by a subsidiary[4] - Cash flow from operating activities for Q1 2025 was 34,515,778.21 RMB, an increase from 12,661,154.43 RMB in Q1 2024[24] - Cash and cash equivalents rose to $534.12 million as of March 31, 2025, compared to $313.23 million at the end of 2024, reflecting a 70.4% increase[13] - Cash and cash equivalents at the end of Q1 2025 totaled 520,565,423.47 RMB, up from 358,957,090.46 RMB at the end of Q1 2024[26] - Total current assets reached $912.87 million as of March 31, 2025, up 27.6% from $715.25 million at the end of 2024[14] Liabilities and Equity - Total liabilities increased to $1.04 billion as of March 31, 2025, compared to $846.22 million at the end of 2024, marking a 23.4% rise[15] - Total equity attributable to shareholders decreased to $1.46 billion as of March 31, 2025, from $1.48 billion at the end of 2024, a decline of 2.4%[16] - Short-term borrowings surged to $397.23 million as of March 31, 2025, compared to $180.16 million at the end of 2024, an increase of 120.5%[15] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 27,687, with the top ten shareholders holding 61.67% of the shares[8] - The company plans to repurchase shares for employee stock ownership plans or equity incentives, as approved by the board[11] Investigations and Other Issues - The company is under investigation for potential criminal activities related to the former vice president's misuse of company seals[11] Research and Development - Research and development expenses increased to $11.06 million in Q1 2025, up 37.8% from $8.02 million in Q1 2024[18] Operating Costs - Total operating costs for Q1 2025 were $193.70 million, down 10.7% from $217.02 million in Q1 2024[18]

Financial Performance - The net profit attributable to shareholders for 2024 was -59,711,716.50 RMB, indicating a loss compared to the previous year[6]. - The parent company achieved a net profit of 4,749,245.32 RMB for 2024, with distributable profits at 24,213,163.03 RMB[6]. - The board proposed no cash dividends, no bonus shares, and no capital increase due to the negative net profit for the year[6]. - The total distributable profits for the consolidated financial statements at the end of 2024 were 319,475,792.10 RMB[6]. - The company's total revenue for the reporting period was CNY 775.73 million, a decrease of 13.28% compared to the same period last year[24]. - The net profit attributable to shareholders was CNY -59.71 million, while the net profit after deducting non-recurring gains and losses was CNY -58.69 million, indicating continued losses[24]. - Cash flow from operating activities was CNY 72.99 million, down 47.94% year-on-year, but still maintained at a relatively good level[32]. - The total assets at the end of the reporting period were CNY 2.41 billion, a decrease of 2.64% compared to the previous year[24]. - The net assets attributable to shareholders decreased by 6.04% to CNY 1.48 billion compared to the previous year[24]. - The company recorded a weighted average return on equity of -3.92%, slightly improved from -3.96% in the previous year[25]. Revenue Segments - The medical services segment generated revenue of CNY 32.14 million, a decline of 9.67% year-on-year, while the medical device segment saw a significant drop of 31.52% to CNY 17.08 million[32]. - The large infusion segment achieved revenue of CNY 276.82 million, remaining stable compared to the previous year, with 3000ml sodium chloride injection contributing CNY 96.17 million, accounting for 34.74% of the infusion segment's revenue[36]. - The Boao International Hospital reported revenue of CNY 16.92 million, with a net profit of CNY 740.16 thousand, both showing a decline year-on-year[34]. - Domestic revenue fell by 17.77% to CNY 625.82 million, while international revenue increased by 9.97% to CNY 143.17 million[69]. Research and Development - The company increased its R&D investment, which contributed to the losses in the medical device and service segments[25]. - Research and development expenses amounted to CNY 41.61 million, representing a significant increase of 43.97% year-on-year, with several innovative drug projects in various stages of development[37]. - The company has developed four core technology platforms in regenerative medicine, including cell storage and clinical research[1]. - The company’s R&D investment as a percentage of net assets is 2.81%[101]. - The company’s R&D investment capitalized ratio is 0.00%, indicating all R&D expenses were expensed in the current period[103]. Corporate Governance and Compliance - The company has a comprehensive governance structure, including a clear division of responsibilities among the board, supervisory committee, and management, ensuring effective oversight and compliance with regulations[123]. - The company has established an independent financial accounting department and adheres to strict financial management protocols to maintain operational independence from controlling shareholders[125]. - The company has implemented measures to strengthen internal controls and enhance supervision to identify and rectify internal control deficiencies[181]. - The company has strengthened employee legal education and compliance training to enhance operational standards and compliance awareness[181]. Market and Industry Outlook - The pharmaceutical industry is expected to face challenges in 2024, with overall revenue stabilizing but profit margins declining compared to the previous year[47]. - The healthcare sector in China saw a total of 1,070,785 medical institutions by the end of 2023, with total health expenditure estimated at CNY 9.06 trillion, an increase of CNY 524.83 billion from 2022[45]. - The medical consumables market in China is projected to reach CNY 200 billion in 2024, with high-value medical consumables accounting for CNY 172.4 billion[46]. Environmental and Social Responsibility - The company has a wastewater treatment facility with a capacity of 80 tons/day and a new facility for needle workshop wastewater treatment with a capacity of 5 tons/day, all operating normally[167]. - The company has implemented a self-monitoring plan for wastewater, including online monitoring every two hours and quarterly sampling for various pollutants[171]. - The company reported a total wastewater discharge of 30.65 tons/year with an average concentration of 165 mg/L for COD[165]. - The company has committed to avoiding any business activities that may compete with its main operations, ensuring compliance with its commitments[177]. - The company made a total donation of 50,000 RMB towards public welfare projects during the reporting period[175]. Shareholder and Capital Management - The company repurchased a total of 12,146,800 shares, accounting for 2.26% of the total share capital, with a total payment of CNY 91.53 million during the first repurchase phase[39]. - Key personnel, including directors and senior management, collectively increased their holdings by 8,838,580 shares, representing 1.65% of the total share capital, with a total investment of CNY 57.10 million[40]. - The company plans to initiate a second share repurchase program with a budget of CNY 100 million to CNY 200 million, with a maximum repurchase price of CNY 10.00 per share[41]. - The company plans to terminate the 2023 stock option incentive plan and cancel the stock options[127]. Legal and Regulatory Matters - The company has a pending lawsuit against Shao Pin for a breach of a share repurchase agreement, with a court ruling requiring Shao Pin to pay 105,762,000 RMB plus overdue interest[184]. - The company has received partial compensation of 285,943.55 RMB from the enforcement of the court ruling against Shao Pin[184]. - The company is actively cooperating with law enforcement regarding the case of "He Qinghong and others forging company seals" to recover losses[180]. - The company has reported a provision for potential losses of 28.3171 million RMB related to a case of forgery involving company seals[179]. Employee Management - The total number of employees in the parent company and major subsidiaries is 1,994, with 677 in the parent company and 1,317 in subsidiaries[147]. - The company has established a comprehensive salary system to ensure fair compensation for employees, promoting continuous business development[149]. - The company has implemented a training program aimed at enhancing the skills and management capabilities of its employees[150]. Investment and Financial Management - The company has entrusted cash asset management with a total of 40,000.00 million RMB in bank wealth management products, with no overdue amounts[194]. - The annualized return rate for bank wealth management products is between 1.50% and 2.60%[196]. - The company has allocated 19,528.15 million RMB for investments in the current year[199]. - The cumulative investment from fundraising as of the reporting period is 48,905.70 million RMB, representing 101.72% of the total fundraising amount[199].